动物造模,柯萨奇病毒A16型感染性模型 zi-bio 2024-03-02 683

　　Objective: To establish a simple and reliable small rodent experimental animal model sensitive to Coxsackie virus A16 type.

　　Method: Long clawed gerbils of different ages were selected, and after intraperitoneal inoculation with CVA16, they were continuously observed for 14 days to screen for the most suitable vaccination age range that is sensitive to the virus; Then compare the relationship between vaccination dose and effect, and determine its 50% lethal dose (LD50); And measure the titer of CVA16 virus in their blood and major tissue organs 3 days after infection; Finally, two doses of CVA16 inactivated vaccine were administered to gerbils at 1 day and 11 days of age. At 14 days of age, LD50 dose virus was used to challenge the gerbils, and the weight, symptoms, and mortality rate of the gerbils were observed and recorded. Two weeks later, blood samples were collected from the eyeballs, and the neutralizing antibody titers and total antibody levels were detected using microneutralization assay and ELISA, respectively.

　　Result: Long clawed gerbils infected with CVA16 showed clinical symptoms such as reduced mobility, hind limb weakness, paralysis, and death. Different age groups of gerbils had different susceptibility to CVA16 infection and the degree of post infection disease. Gerbils at 7 and 14 days of age were more susceptible, while those at 28 days of age were less susceptible. The most sensitive and suitable vaccination age was 14 days of age, with a LD50 of 1 × 104.5 CCID50, After 3 days of infection, high titers of CVA16 virus were detected in both the blood and major tissues and organs. Fourteen day old gerbils immunized with two doses of inactivated vaccine were challenged with LD50 dose, resulting in a survival rate of 87.5%. The geometric mean (GMT) of CVA16 neutralizing antibodies produced by the vaccine induced gerbils was 28.14, and the antibody positivity rate was 87.5%.

　　Conclusion: Long clawed gerbils are sensitive to CVA16 and can effectively replicate and reproduce the virus in their bodies, making them a reliable small animal model for studying the pathogenesis of CVA16, vaccine development, and drug evaluation.